LEI-106

LEI-106 is a potent, dual sn-1-Diacylglycerol lipase α (DAGL-α) /ABHD6 inhibitor with an IC50 of 18 nM for DAGL-α and a Ki of 0.8 μM for ABHD6. LEI-106 inhibits the hydrolysis of [14C]-sn-1-oleoyl-2-arachidonoyl-glycerol, the natural substrate of DAGL-α, with a Ki of 0.7 μM[1].

Product Specifications

CAS Number

[1620582-23-1]

UNSPSC

12352005

Target

DAGL; MAGL

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/lei-106.html

Purity

99.9

Solubility

10 mM in DMSO

Smiles

OC(CN(CC1=CC=C(OC2=CC=CC=C2)C=C1)S(C3=CC=C4OC(C)(CCC4=C3)C)(=O)=O)=O

Molecular Formula

C26H27NO6S

Molecular Weight

481.56

References & Citations

[1]Janssen FJ, et al. Discovery of glycine sulfonamides as dual inhibitors of sn-1-diacylglycerol lipase α and α/β-hydrolase domain 6. J Med Chem. 2014;57 (15) :6610-6622.